Tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) is being used more widely across
the world to treat HIV. This is an observational study (a type of study in which participants
are observed and certain outcomes are measured). The aim of this study is to observe how
successful TLD is at treating HIV, in the following groups of people:
People switching to TLD, after taking anti-HIV medication that contains a nonnucleoside
reverse transcriptase inhibitor (NNRTI) drug (such as Efavirenz or Nevirapine) (Group
People switching to TLD, after taking anti-HIV medication that contains a boosted
protease inhibitor (PI) drug (such as Lopinavir or Atazanavir) (Group 2).
People taking TLD and receiving medication for TB that includes the drug rifampicin
(RIF) (Group 3). These people must be starting one or both of these medications when
they enter the study.
People starting TLD who have not taken anti-HIV medication before (Group 4).
Another goal of this study is to use genetic testing of the virus (HIV) to see how often HIV
is resistant to TLD. Genetic testing of the virus is one way to see if the TLD medication is
not working to treat a person's HIV infection.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.